Revance Therapeutics (RVNC) Misses Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Revance Therapeutics (RVNC) Misses Q2 EPS by 12c

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

August 9, 2022 4:05 PM EDT

PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines Second quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 million Aesthetic accounts across products and services totaled over 4,000 at quarter-end Revance launches RHA® Redensity for the treatment of moderate to severe perioral rhytids (lip lines) Conference call and webcast today at 4:30 p.m. ET.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More